We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

124 hedge funds and large institutions have $58.3M invested in Akebia Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 43 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more call options, than puts

Call options by funds: $4.35M | Put options by funds: $2.64M

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

7% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 43

7% less funds holding

Funds holding: 133 → 124 (-9)

10.52% less ownership

Funds ownership: 55.34% → 44.82% (-11%)

35% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 26

73% less capital invested

Capital invested by funds: $218M → $58.3M (-$160M)

Holders
124
Holders Change
-9
Holders Change %
-6.77%
% of All Funds
1.96%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
40
Reduced
43
Closed
26
Calls
$4.35M
Puts
$2.64M
Net Calls
+$1.71M
Net Calls Change
-$2.82M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.5M
2
Millennium Management
Millennium Management
New York
+$1.51M
3
Renaissance Technologies
Renaissance Technologies
New York
+$814K
4
Group One Trading
Group One Trading
Illinois
+$721K
5
UBS Group
UBS Group
Switzerland
+$614K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$10.5M
2
Marshall Wace
Marshall Wace
United Kingdom
-$10.1M
3
WP
Woodline Partners
California
-$5.04M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$3.75M
5
Goldman Sachs
Goldman Sachs
New York
-$2.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
26
Group One Trading
Illinois
$289K +$721K +336,783 +515%
Swiss National Bank
27
Swiss National Bank
Switzerland
$282K +$60.5K +28,300 +8%
Allspring Global Investments
28
Allspring Global Investments
North Carolina
$251K +$89.3K +41,740 +14%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$244K -$131K -61,200 -15%
CS
30
Credit Suisse
Switzerland
$233K +$3.13K +1,463 +0.5%
Wellington Management Group
31
Wellington Management Group
Massachusetts
$227K +$5.99K +2,801 +0.9%
SFI
32
Susquehanna Fundamental Investments
Pennsylvania
$222K – – –
Wells Fargo
33
Wells Fargo
California
$212K -$112K -52,320 -15%
SO
34
STRS Ohio
Ohio
$204K – – –
Invesco
35
Invesco
Georgia
$201K +$192K +89,594 +47%
Russell Investments Group
36
Russell Investments Group
United Kingdom
$182K -$129K -60,080 -19%
PAM
37
Panagora Asset Management
Massachusetts
$180K +$499 +233 +0.1%
Prudential Financial
38
Prudential Financial
New Jersey
$177K -$815K -381,000 -60%
BFM
39
Boothbay Fund Management
New York
$177K +$493K +230,477 +1,457%
Citigroup
40
Citigroup
New York
$170K -$940K -439,396 -65%
ECM
41
ExodusPoint Capital Management
New York
$161K +$137K +64,033 +40%
Fidelity Investments
42
Fidelity Investments
Massachusetts
$161K +$479K +224,001 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$155K -$41.8K -19,524 -8%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$147K -$12.9K -6,053 -3%
Principal Financial Group
45
Principal Financial Group
Iowa
$132K -$158K -73,624 -28%
AQR Capital Management
46
AQR Capital Management
Connecticut
$132K +$220K +102,691 +126%
UBS AM
47
UBS AM
Illinois
$130K – – –
AllianceBernstein
48
AllianceBernstein
Tennessee
$108K +$1.5K +700 +0.5%
Tudor Investment Corp
49
Tudor Investment Corp
Connecticut
$106K +$288K +134,622 +1,070%
VF
50
Virtu Financial
New York
$94K +$280K +130,949 New
1
2
3 4 5

AKBA Hedge Fund Activity: Q1 2022 in Review

124 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2022, worth a combined $58.3M — down 73% from $218M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of AKBA and 17 opened new positions — a net loss of 9 holders — while 43 trimmed existing stakes and 40 added.

The largest buyer was Vanguard Group, adding an estimated $2.5M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $10.5M sold.

  • 124 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2022, down from 133 in Q4 2021.
  • Funds reported $58.3M of Akebia Therapeutics stock for Q1 2022, down 73% quarter-over-quarter.
  • 17 funds opened new Akebia Therapeutics positions in Q1 2022 and 26 closed out, a net change of -9 holders.
  • The largest Akebia Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $2.5M added.
  • The largest Akebia Therapeutics seller in Q1 2022 was Nantahala Capital Management, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2022.